ACG Case Reports Journal
Cure8 research brief
Why This Matters
Atypical HUS is a rare, potentially life-threatening thrombotic microangiopathy that can be triggered by systemic inflammation such as IBD. Early recognition and complement testing can change management and may lead to treatment (eculizumab) that improved this patient in the report.
Who Should Pay Attention
Clinicians managing IBD (especially inpatient or severe flares), hospitalists, nephrologists, and adult IBD patients with new anemia, thrombocytopenia, or acute kidney injury.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This case report describes a patient with inflammatory bowel disease who developed atypical hemolytic uremic syndrome (a thrombotic microangiopathy linked to complement dysregulation). The patient presented with abdominal pain and melena and had laboratory evidence of hemolytic anemia, low platelets, and acute kidney injury.
Testing supported a diagnosis of atypical HUS and treatment with eculizumab was started, with reported rapid improvement in hemolysis, platelet count, and kidney function.
Keep In Mind
This classification and brief are grounded in the article abstract/case report. Case reports describe individual patients and should not be generalized; they are useful for raising awareness of rare complications.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationACG Case Reports Journal
AuthorsPatrick J. Ryan, Megan Walker, Satya Kurada
InstitutionIndiana University School of Medicine
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedSep 25, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Visceral Leishmaniasis-Associated Hemophagocytic Lymphohistiocytosis in a Patient With Crohn's Disease in Therapy With Anti-TNFα: A Challenging Diagnostic Case Report.
HLH is a rare but serious complication in immunosuppressed IBD patients; visceral leishmaniasis can trigger HLH and may be overlooked outside endemic areas. Early bone marrow assessment can speed diagnosis and treatment.
Visceral Leishmaniasis–Associated Hemophagocytic Lymphohistiocytosis in a Patient With Crohn’s Disease in Therapy With Anti‐TNFα: A Challenging Diagnostic Case Report
People with Crohn’s disease on anti‑TNF biologics can rarely develop severe infections that trigger life‑threatening hyperinflammatory syndromes like HLH. Early recognition and bone marrow testing can identify treatable...
Mesalazine-induced myocarditis following dose escalation in ulcerative colitis: a diagnostic challenge
Mesalazine is commonly used in ulcerative colitis; recognizing rare but serious myocarditis linked to it can lead to rapid treatment changes and recovery. Distinguishing drug-induced myocarditis from IBD-related...